Literature DB >> 25860813

Correction: Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha.

.   

Abstract

Entities:  

Year:  2015        PMID: 25860813      PMCID: PMC4393263          DOI: 10.1371/journal.pone.0124463

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


× No keyword cloud information.
There is an error in Fig 8. The upper panel of the figure was omitted. Please see the corrected Fig 8 here.
Fig 8

Antiviral efficacy of mIFNα2-dAb fusions and PEGylated mIFNα2 following intravenous administration.

Effect of single-dose liver-targeted IFN-α on liver HBV DNA using Southern blot hybridization (upper panel) and quantitative PCR (lower panel) in HBV transgenic mice. For statistical analysis, the data were transformed to natural log for one-way analysis of variance, after which Bonferroni’s comparison analysis was performed. (*P < 0.05, **P < 0.01, ***P < 0.001 compared to vehicle control values).

Antiviral efficacy of mIFNα2-dAb fusions and PEGylated mIFNα2 following intravenous administration.

Effect of single-dose liver-targeted IFN-α on liver HBV DNA using Southern blot hybridization (upper panel) and quantitative PCR (lower panel) in HBV transgenic mice. For statistical analysis, the data were transformed to natural log for one-way analysis of variance, after which Bonferroni’s comparison analysis was performed. (*P < 0.05, **P < 0.01, ***P < 0.001 compared to vehicle control values).
  1 in total

1.  Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha.

Authors:  Daniel Rycroft; Jane Sosabowski; Edward Coulstock; Marie Davies; John Morrey; Sarah Friel; Fiona Kelly; Robert Hamatake; Milan Ovečka; Rob Prince; Laura Goodall; Armin Sepp; Adam Walker
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.